NCT06879158View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

January 26, 2025

Study Completion Date

January 26, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

BR3409

One tablet administered alone

DRUG

BR3409-1

One tablet administered alone

DRUG

BR3409-2

One tablet administered alone

Trial Locations (1)

08779

Clinical Research Center, H PLUS Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT06879158 - A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions | Biotech Hunter | Biotech Hunter